Trial Profile
Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs JNJ 90009530 (Primary)
- Indications B-cell lymphoma
- Focus Therapeutic Use
- Sponsors Beijing Biohealthcare Biotechnology
- 23 Nov 2016 New trial record